Pre-Clinical Research

Found 6,193 articles

• New Imeglimin Data Demonstrating Pancreatic Beta-Cell Protection Presented at the American Diabetes Association 78th Scientific Sessions

  6/25/2018

  Imeglimin was observed to protect and preserve human beta-cells from cell death from fructose- and glucose-induced toxicity by inhibiting mitochondrial Permeability Transition Pore opening

• 

  J&J Opens its JLABS @ NYC Business Incubator With 26 Companies in Place

  6/22/2018

  After waiting with bated breath, Johnson & Johnson Innovation finally opened its New York City JLABS facility with 26 resident companies, including the four winners of the JLABS @ NYC QuickFire Challenge.
• 

  Autolus Brings in $150 Million in IPO, Continues Strong Investment Trend for Biotechs This Week

  6/22/2018

  Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.

• Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells

  6/21/2018

  Further preclinical findings support a best-in-class profile

• Ironwood Pharmaceuticals Initiates Pivotal Phase III Program for IW-3718 in Persistent Gastroesophageal Reflux Disease

  6/21/2018

  Program Designed to Support U.S. Regulatory Filing of IW-3718 as Potential Treatment for Patients Who Continue to Suffer From GERD Despite Receiving Standard of Care.

• 

  TG Therapeutics and Novimmune Forge $185M Agreement

  6/20/2018

  TG Therapeutics and Novimmune SA struck a collaborative deal worth up to $185 million on the development and commercialization of a treatment for hematologic B-cell malignancies.

• Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

  6/19/2018

  Caladrius Biosciences, Inc. announces today that that the U.S. Food and Drug Administration has granted RMAT designation to the Company’s late-stage CD34+ cell therapy program.

• OWC Pharmaceutical Research Corp Completes Development of Next Generation Orally-Disintegrating Tablet

  6/13/2018

  OWC Pharmaceutical Research Corp. announced it has completed the pre-clinical development of its next generation, orally-disintegrating tablet containing cannabis extract with specific amounts of the cannabinoids tetrahydrocannabinol ("THC") and cannabidiol ("CBD").

• Protalex Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in a Mouse Model of Myasthenia Gravis

  6/12/2018

  Findings Support Advancement of PRTX-100 into its Third Clinical Indication.

• ExThera Medical Announces Completion of CE Mark Registration Trial Evaluating the Safety of Seraph® 100 Blood Filter

  6/11/2018

  ExThera Medical Corporation today announced that it completed its CE Mark registration trial evaluating the safety of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph) in renal replacement therapy patients who developed bacteremia.

• Verseon Presents New Data on its Precision Oral Anticoagulants at BIO International Convention

  6/11/2018

  Verseon presented new preclinical data on its novel class of precision oral anticoagulants (PROACs) at last week’s BIO International Convention in Boston.

• Eloxx Pharmaceuticals Presents Positive New Data for Lead Investigational Drug, ELX-02, at the 41st European Cystic Fibrosis Conference (ECFS)

  6/11/2018

  Eloxx Pharmaceuticals, Inc. (“Eloxx”), (Nasdaq:ELOX), today announced positive data demonstrating that ELX-02 restores transmembrane conductance in and promotes forskolin-induced swelling (FIS).

• Can-Fite Reports on New Pre-Clinical Developments with Its NASH Drug Namodenoson

  6/11/2018

  Can-Fite BioPharma Ltd. today provided an update on new pre-clinical data supporting the selection of the primary endpoint for the current ongoing Phase II study in NAFLD/NASH patients.

• New Data Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication

  6/7/2018

  Artemis Therapeutics, Inc. (OTCQB: ATMS), ("Artemis" or the "Company"), today announced that new data on its lead product candidate Artemisone shows it is a potent inhibitor of human cytomegalovirus (HCMV).

• Atreca to Present Immuno-Oncology Research Findings at 2018 World Preclinical Congress

  6/7/2018

  Atreca, Inc. announced today that Norman Michael Greenberg, Ph.D., Senior Vice President and Chief Scientific Officer at Atreca, will deliver a presentation during the 2018 World Preclinical Congress (WPC) Annual Meeting.

• CardioNXT Announces Enrollment Completion of RADAR Clinical Trial

  6/6/2018

  CardioNXT and AFTx, related privately-held medical device companies, jointly announced today that the Real-time electrogram Analysis for Drivers of Atrial fibRillation (RADAR) clinical trial has reached full enrollment with 65 treated patients.

• Synlogic Presents New Preclinical Data from Synthetic BioticTM Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®

  6/4/2018

  SYNB1020 currently being evaluated in a Phase 1b/2a clinical trial in patients with elevated ammonia due to cirrhosis; topline data expected by YE2018.

• Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®

  6/4/2018

  Synlogic, Inc. announced that new preclinical data from SYNB1020, a Synthetic Biotic medicine currently being evaluated in an ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia, were presented at Digestive Disease Week (DDW 2018)

• Nordic Nanovector to Present Pre-clinical Study of Betalutin® Effect on NHL Cells at European Hematology Association Meeting

  5/31/2018

  Nordic Nanovector ASA announces that it will present a poster describing a preclinical analysis of genetic factors that correlate with the responsiveness of non-Hodgkin's lymphoma (NHL) cell lines to Betalutin® (177Lu-lilotomab satetraxetan) at the 23rd annual meeting of the European Hematology Association (EHA) (Stockholm, Sweden, 14-17 June).

• Early Intervention of Hemorrhagic Stroke Trial Reaches 100 Patients

  5/31/2018

  More than 100 subjects are now enrolled in the ENRICH randomized controlled trial designed to compare the outcomes between early surgical intervention of clot removal using the minimally disruptive BrainPath® Approach (NICO Corporation) and the "watch and see" medical management standard of care.